Patents Examined by Sergio Coffa
  • Patent number: 11174299
    Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence consisting of SVHSFDYDWYNV, or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: November 16, 2021
    Assignee: DISPERSEBIO LTD.
    Inventor: Amir Zlotkin
  • Patent number: 11168113
    Abstract: (Technical problems to be solved) Providing a method for selecting an mineral of molybdenum. (Means for solving the problems) A peptide comprising an amino acids sequence according the following formula (1) and/or (2): (1) (ALRKNMD-FCPQSETGWHYIV)-(LIVFA)-(HPWRK)-(TSNQ)-(TSNQ)-(LIVFA)-(TSNQ)-(TSNQ)-(LIVFA)-(FYW)-(LIVFA)-(HPWRK) (2) (LIVFA)-(RHK)-(TSNQ)-(LIVFA)-(LIVFA)-(TSNQ)-(LIVFA)-(LIVFA)-(LIVFA)-(RHK)-(RHK)-(HPW) wherein one amino acid is respectively selected from each group defined by paired parentheses.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: November 9, 2021
    Assignees: SHIBAURA INSTITUTE OF TECHNOLOGY, JX NIPPON MINING & METALS CORPORATION
    Inventors: Mitsuo Yamashita, Akira Miura
  • Patent number: 11155582
    Abstract: An antiviral peptide provided according to the present invention includes (1) an amino acid sequence (TM sequence) constituting a transmembrane region of G protein of vesicular stomatitis virus (VSV) or a modified amino acid sequence formed by conservative substitutions of 1, 2, or 3 amino acid residues in the TM sequence; and (2) an amino acid sequence (CPP sequence) functioning as a cell penetrating peptide (CPP), wherein a total number of amino acid residues is 100 or less.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: October 26, 2021
    Assignees: TOAGOSEI CO., LTD, National University Corporation Hokkaido University
    Inventors: Tetsuhiko Yoshida, Ayato Takada, Nahoko Baileykobayashi
  • Patent number: 11147856
    Abstract: The present invention relates to hot flash-suppressing agents and menopausal disorder-improving agents and a food and drink and a pharmaceutical preparation for suppressing hot flash, containing ?-lactalbumin as an active ingredient.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: October 19, 2021
    Assignee: MEIJI CO., LTD.
    Inventors: Masayuki Uchida, Orie Kobayashi
  • Patent number: 11142562
    Abstract: The present invention relates to a novel peptide that exhibits effective antimicrobial activity against various gram-positive and gram-negative bacteria that are involved in food-borne pathogenesis, food spoilage and other pathogenic conditions. Therefore, this peptide can be a good candidate as antibacterial in agricultural, food and beverage industry, as well as for other medical applications and societal use.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: October 12, 2021
    Assignee: Council of Scientific & Industrial Research
    Inventors: Balaji Prakash, Yashavanth Linganamane, Abhishek Acharya
  • Patent number: 11141461
    Abstract: The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide is between 12 and 28 amino acids in length and comprises an amino acid sequence according to SEQ ID NO: 16 or a variant thereof according to formula 2, wherein the amino acid sequence of said peptide is comprised in SEQ ID NO: 34 or a variant thereof according to formula 1.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: October 12, 2021
    Assignee: Chondropeptix
    Inventors: Tim Johannes Maria Welting, Marjolein Maria Johanna Caron
  • Patent number: 11141462
    Abstract: The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide consists of an amino acid sequence according to SEQ ID NO: 18 or an analogue thereof, wherein the analogue is a peptide consisting of an amino acid sequence according to formula 1 (SEQ ID NO: 29), or a fragment thereof wherein the fragment consists of at least 10 consecutive amino acids of SEQ ID NO: 18 or an amino acid sequence according to formula 1.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: October 12, 2021
    Assignee: Chondropeptix B.V.
    Inventors: Tim Johannes Maria Welting, Marjolein Maria Johanna Caron
  • Patent number: 11130783
    Abstract: The present disclosure is related to compositions comprising peptides that bind CD40 and methods of use in inhibiting interaction of CD40 and CD154 and inducing immunosuppression. Provided herein are methods of transplantation and methods of inhibiting donor specific immune response. Also provided herein are methods of treatment for autoimmune diseases, inflammatory diseases and cancer.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: September 28, 2021
    Assignees: Regents of the University of Minnesota, Diabetes-Free, Inc.
    Inventors: Bernhard J. Hering, Sabarinathan Ramachandran, Prashant Girinath
  • Patent number: 11123406
    Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: September 21, 2021
    Assignee: Eli Lilly and Company
    Inventors: Michael Patrick Akers, Chi A. Nguyen, Chad D. Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte, Ranajoy Majumdar
  • Patent number: 11091515
    Abstract: The present invention relates to a polypeptide derived from CAP1 and a pharmaceutical composition comprising the same as an effective ingredient and, more particularly, to a peptide including the amino acid sequence of SEQ ID NO: 1, any 0 to 20 amino acid residues added to the N terminus thereof, and any 0 to 75 amino acid residues added to the C terminus thereof, and a pharmaceutical composition comprising the peptide as an effective ingredient for the prevention and alleviation of inflammatory diseases, the inhibition of cancer and cancer metastasis, the prevention and alleviation of diabetes, the prevention and alleviation of arteriosclerosis or cardiovascular diseases, and the prevention and alleviation of heart failure.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: August 17, 2021
    Assignee: SEOUL NATIONAL UNIVERSITY HOSPITAL
    Inventors: Hyo Soo Kim, Hyun Duk Jang, Sang Eun Lee
  • Patent number: 11058743
    Abstract: The present invention provides compositions and formulations comprising glutathione with or without thiocyanate and methods of use thereof to treat diseases and disorders in mucosal/epithelial tissue.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: July 13, 2021
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Roland R. Arnold, David C. Henke
  • Patent number: 11033607
    Abstract: Provided are GLP-1 C-terminal peptides and methods of use for the treatment or prevention of ischemic tissue injury. The peptides correspond to GLP-1(28-36). FIAWLVKGR and GLP-1(28-37) FIAWLVKGRG and are useful in the treatment or prevention of ischemic tissue injury, including ischemic heart disease or stroke.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: June 15, 2021
    Assignee: University Health Network
    Inventors: Mansoor Husain, Dhanwantee Mundil
  • Patent number: 11034728
    Abstract: A polypeptide having a sequence at least 70% identical to SEQ ID NO: 1 (YVSPGMKNVNWWSHWWHATD) is provided. The polypeptide includes no more than 100 total amino acid residues.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: June 15, 2021
    Assignee: 3M Innovative Properties Company
    Inventors: Minghua Dai, Amy K. McNulty, Federica Sgolastra, Jie Liu, Jana Ninkovic, Robert T. Fitzsimons, Jr.
  • Patent number: 11014974
    Abstract: Provided is a non-antibody binding protein binding to PD-1 receptor which has a sequence as shown in SEQ ID NO:1 and its analogues. Also provided is use of the non-antibody binding protein in the preparation of a formulation for treating PD-1 pathway related diseases.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: May 25, 2021
    Assignees: ORAL SUBSIDIARY SUN YAT-SEN UNIVERSITY HOSPITAL, GUANGZHOU YIDAI PHARMACEUTICAL CO., LTD.
    Inventors: Hua Wang, Xiaofeng Huang, Long Zhao, Yan Zhang
  • Patent number: 11008366
    Abstract: The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: May 18, 2021
    Assignee: AILERON THERAPEUTICS, INC.
    Inventors: Vincent Guerlavais, Noriyuki Kawahata
  • Patent number: 10995119
    Abstract: The present invention provides a novel molecule that catalyzes a hydrolysis reaction and is different from enzyme proteins. The catalytic peptide according to the present invention is a catalytic peptide that catalyzes a hydrolysis reaction, including at least one peptide selected from the group consisting of the following peptides (A1) to (A4): (A1) a peptide consisting of Box A and at least one of an upstream region and a downstream region therefrom in a Tob/BTG protein; (A2) a peptide consisting of a partial region of the peptide (A1); (A3) a peptide that consists of an amino acid sequence obtained by deletion, substitution, addition, and/or insertion of one or more amino acids in an amino acid sequence of the peptide (A1) or (A2) and has hydrolysis activity; and (A4) a peptide consisting of an amino acid sequence with a sequence identity of at least 85% to the amino acid sequence of the peptide (A1) or (A2) and having hydrolysis activity.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: May 4, 2021
    Assignee: OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION
    Inventors: Toshifumi Akizawa, Tadashi Yamamoto
  • Patent number: 10988506
    Abstract: Cyclic tetrapeptide stereochemical isomers of CJ-15,208, pharmaceutical compositions from such cyclic tetrapeptides, and methods of using such pharmaceutical compositions. The cyclic tetrapeptide compounds and pharmaceutical compositions disclosed herein are potent analgesics active in several pain models with generally minimal tolerance and reduced likelihood to induce addiction relative to other known opiates.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: April 27, 2021
    Assignee: University of Kansas
    Inventors: Jane V. Aldrich, S P Sanjeewa Nilendra Senadheera
  • Patent number: 10961547
    Abstract: Described are nanoparticulates comprising a metallic nanoparticle core and a peptide coating or shell encapsulating the nanoparticle core and being covalently bonded thereto. The coating is formed from a plurality of branched, amphipathic peptides, each comprising a polar/positively charged C-terminal segment, a branch point, and two hydrophobic N-terminal segments extending from the branch point. Methods of forming and using the nanoparticulates are also described. When a plurality of first and second peptides are added sequentially to the nanoparticle core, the peptides they self-assemble to form an interlocking peptide network bilayer where the respective hydrophobic segments of the peptides form beta-sheet structures in which the opposed sequences interlock to form a zipper-like structure in three dimensions.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: March 30, 2021
    Assignee: Kansas State University Research Foundation
    Inventors: John M. Tomich, Pinakin R. Sukthankar
  • Patent number: 10961276
    Abstract: The present disclosure is directed to a universal antivenom for the treatment of venomous animal bites, and methods of developing the same using a novel targeted phage display technique.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: March 30, 2021
    Assignee: CAMRIS International, Inc.
    Inventor: Yoon Y. Hwang
  • Patent number: 10954271
    Abstract: Described herein are anti-microbial peptides having enhanced activity and transport.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: March 23, 2021
    Assignee: Tensive Controls, Inc.
    Inventor: Kenneth Allen Gruber